Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2011, Article ID 287574, 10 pages
http://dx.doi.org/10.1155/2011/287574
Review Article

Biologics in Paediatric Crohn's Disease

1Department of Paediatrics, Monash University, Clayton, VIC 3800, Australia
2Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville Melbourne, VIC 3052, Australia
3Gut and Liver Group, Murdoch Childrens Research Institute, Parkville, VIC 3052, Australia
4Department of Paediatrics, University of Melbourne, Melbourne, VIC 3052, Australia

Received 25 April 2011; Revised 10 July 2011; Accepted 1 October 2011

Academic Editor: Peter M. Irving

Copyright © 2011 Oliver Gouldthorpe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. I. Benchimol, K. J. Fortinsky, P. Gozdyra, M. Van Den Heuvel, J. Van Limbergen, and A. M. Griffiths, “Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 423–439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Phavichitr, D. J. S. Cameron, and A. G. Catto-Smith, “Increasing incidence of Crohn's disease in Victorian children,” Journal of Gastroenterology and Hepatology, vol. 18, no. 3, pp. 329–332, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. E. V. Loftus Jr., “Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences,” Gastroenterology, vol. 126, no. 6, pp. 1504–1517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Bernklev, J. Jahnsen, I. Lygren, M. Henriksen, M. Vatn, and B. Moum, “Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms,” Inflammatory Bowel Diseases, vol. 11, no. 10, pp. 909–918, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. D. Kappelman, C. Q. Porter, J. A. Galanko et al., “Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 62–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. C. Kim and G. D. Ferry, “Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations,” Gastroenterology, vol. 126, no. 6, pp. 1550–1560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. G. Sauer and S. Kugathasan, “Pediatric inflammatory Bowel disease: highlighting pediatric differences in IBD,” Gastroenterology Clinics of North America, vol. 38, no. 4, pp. 611–628, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Vernier-Massouille, M. Balde, J. Salleron et al., “Natural history of pediatric Crohn's disease: a population-based cohort study,” Gastroenterology, vol. 135, no. 4, pp. 1106–1113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Van Limbergen, R. K. Russell, H. E. Drummond et al., “Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease,” Gastroenterology, vol. 135, no. 4, pp. 1114–1122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Paul, A. Birnbaum, D. K. Pal et al., “Distinct phenotype of early childhood inflammatory bowel disease,” Journal of Clinical Gastroenterology, vol. 40, no. 7, pp. 583–586, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Polito II, B. Childs, E. D. Mellits, A. Z. Tokayer, M. L. Harris, and T. M. Bayless, “Crohn's disease: influence of age at diagnosis on site and clinical type of disease,” Gastroenterology, vol. 111, no. 3, pp. 580–586, 1996. View at Google Scholar · View at Scopus
  12. H. J. Freeman, “Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence,” Canadian Journal of Gastroenterology, vol. 18, no. 11, pp. 661–665, 2004. View at Google Scholar · View at Scopus
  13. S. Kugathasan and S. Cohen, “Searching for new clues in inflammatory bowel disease: tell tales from pediatric IBD natural history studies,” Gastroenterology, vol. 135, no. 4, pp. 1038–1041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Imielinski, R. N. Baldassano, A. Griffiths et al., “Common variants at five new loci associated with early-onset inflammatory bowel disease,” Nature Genetics, vol. 41, no. 12, pp. 1335–1340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Vermeire, G. van Assche, and P. Rutgeerts, “Role of genetics in prediction of disease course and response to therapy,” World Journal of Gastroenterology, vol. 16, no. 21, pp. 2609–2615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Borrelli, L. Cordischi, M. Cirulli et al., “Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial,” Clinical Gastroenterology and Hepatology, vol. 4, no. 6, pp. 744–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Markowitz, K. Grancher, N. Kohn, M. Lesser, and F. Daum, “A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease,” Gastroenterology, vol. 119, no. 4, pp. 895–902, 2000. View at Google Scholar · View at Scopus
  18. C. Prantera, F. Zannoni, M. L. Scribano et al., “An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin,” American Journal of Gastroenterology, vol. 91, no. 2, pp. 328–332, 1996. View at Google Scholar · View at Scopus
  19. J. P. Cezard, A. Munck, O. Mouterde et al., “Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial,” Gastroenterologie Clinique et Biologique, vol. 33, no. 1, pp. 31–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Markowitz, “Early inflammatory bowel disease: different treatment response to specific or all medications?” Digestive Diseases, vol. 27, no. 3, pp. 358–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Tung, E. V. Loftus, D. K. Freese et al., “A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis,” Inflammatory Bowel Diseases, vol. 12, no. 12, pp. 1093–1100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Goodhand, R. Dawson, M. Hefferon et al., “Inflammatory bowel disease in young people: the case for transitional clinics,” Inflammatory Bowel Diseases, vol. 16, no. 6, pp. 947–952, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Wong, D. Ziring, Y. Korin et al., “TNFα blockade in human diseases: mechanisms and future directions,” Clinical Immunology, vol. 126, no. 2, pp. 121–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. D. M. Knight, H. Trinh, J. Le et al., “Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,” Molecular Immunology, vol. 30, no. 16, pp. 1443–1453, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Van Assche, S. Vermeire, and P. Rutgeerts, “Infliximab therapy for patients with inflammatory bowel disease: 10 years on,” European Journal of Pharmacology, vol. 623, no. 1, pp. S17–S25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Bousvaros, “Use of immunomodulators and biologic therapies in children with inflammatory bowel disease,” Expert Review of Clinical Immunology, vol. 6, no. 4, pp. 659–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Markowitz, J. Rosa, K. Grancher, H. Aiges, and F. Daum, “Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease,” Gastroenterology, vol. 99, no. 5, pp. 1347–1351, 1990. View at Google Scholar · View at Scopus
  28. S. B. Hanauer, “Crohn's disease: step up or top down therapy,” Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 17, no. 1, pp. 131–137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. G. R. D'Haens, “Top-down therapy for IBD: rationale and requisite evidence,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 2, pp. 86–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. S. Hyams, G. D. Ferry, F. S. Mandel et al., “Development and validation of a pediatric Crohn's disease activity index,” Journal of Pediatric Gastroenterology and Nutrition, vol. 12, no. 4, pp. 439–447, 1991. View at Google Scholar · View at Scopus
  31. W. R. Best, J. M. Becktel, J. W. Singleton, and F. Kern, “Development of a Crohn's disease activity index. National cooperative Crohn's disease study,” Gastroenterology, vol. 70, no. 3, pp. 439–444, 1976. View at Google Scholar · View at Scopus
  32. D. Turner, A. M. Griffiths, T. D. Walters et al., “Appraisal of the pediatric crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties,” American Journal of Gastroenterology, vol. 105, no. 9, pp. 2085–2092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. G. D'Haens, “Mucosal healing in pediatric Crohn's disease: the goal of medical treatment,” Inflammatory Bowel Diseases, vol. 10, no. 4, pp. 479–480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. R. Targan, S. B. Hanauer, S. J. H. van Deventer et al., “A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease,” The New England Journal of Medicine, vol. 337, no. 15, pp. 1029–35, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. S. B. Hanauer, B. G. Feagan, G. R. Lichtenstein et al., “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial,” The Lancet, vol. 359, no. 9317, pp. 1541–1549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. B. E. Sands, F. H. Anderson, C. N. Bernstein et al., “Infliximab maintenance therapy for fistulizing Crohn's disease,” The New England Journal of Medicine, vol. 350, no. 9, pp. 876–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. OECBM Levels of Evidence Working Group, The Oxford 2011 Levels of Evidence, Oxford Centre for Evidence-Based Medicine, 2011.
  38. R. Baldassano, C. P. Braegger, J. C. Escher et al., “Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease,” American Journal of Gastroenterology, vol. 98, no. 4, pp. 833–838, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. J. P. Cezard, N. Nouaili, C. Talbotec et al., “A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 36, no. 5, pp. 632–636, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Hyams, W. Crandall, S. Kugathasan et al., “Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children,” Gastroenterology, vol. 132, no. 3, pp. 863–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. F. M. Ruemmele, A. Lachaux, J. P. Cézard et al., “Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy,” Inflammatory Bowel Diseases, vol. 15, no. 3, pp. 388–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. R. F. Harvey and J. M. Bradshaw, “A simple index of Crohn's-disease activity,” The Lancet, vol. 1, no. 8167, p. 514, 1980. View at Google Scholar · View at Scopus
  44. W. R. Best, “Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index,” Inflammatory Bowel Diseases, vol. 12, no. 4, pp. 304–310, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. S. Hyams, T. Lerer, A. Griffiths et al., “Long-term outcome of maintenance infliximab therapy in children with Crohn's disease,” Inflammatory Bowel Diseases, vol. 15, no. 6, pp. 816–822, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. S. B. Hanauer, C. L. Wagner, M. Bala et al., “Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease,” Clinical Gastroenterology and Hepatology, vol. 2, no. 7, pp. 542–553, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Candon, A. Mosca, F. Ruemmele, O. Goulet, L. Chatenoud, and J. P. Cézard, “Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease,” Clinical Immunology, vol. 118, no. 1, pp. 11–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Vermeire, M. Noman, G. Van Assche, F. Baert, G. D'Haens, and P. Rutgeerts, “Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease,” Gut, vol. 56, no. 9, pp. 1226–1231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. G. J. Mantzaris, N. Viazis, K. Petraki et al., “A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab,” European Journal of Gastroenterology and Hepatology, vol. 21, no. 9, pp. 1042–1048, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Kugathasan, L. J. Saubermann, L. Smith et al., “Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease,” Gut, vol. 56, no. 12, pp. 1696–1705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Kim, J. S. Lee, J. H. Lee, J. Y. Kim, and Y. H. Choe, “Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing “top-down” and “step-up” strategies,” Acta Paediatrica, vol. 100, no. 3, pp. 451–455, 2011. View at Publisher · View at Google Scholar
  52. M. C. Dubinsky, L. Mei, M. Friedman et al., “Genome Wide Association (GWA) predictors of anti-TNFα therapeutic responsiveness in pediatric inflammatory bowel desease,” Inflammatory Bowel Diseases, vol. 16, no. 8, pp. 1357–1366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. W. J. Sandborn, S. B. Hanauer, P. Rutgeerts et al., “Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial,” Gut, vol. 56, no. 9, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. B. G. Feagan, R. Panaccione, W. J. Sandborn et al., “Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study,” Gastroenterology, vol. 135, no. 5, pp. 1493–1499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Swoger, E. V. Loftus Jr., W. J. Tremaine et al., “Adalimumab for Crohns disease in clinical practice at Mayo clinic: the first 118 patients,” Inflammatory Bowel Diseases, vol. 16, no. 11, pp. 1912–1921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Viola, F. Civitelli, G. Di Nardo et al., “Efficacy of adalimumab in moderate-to-severe pediatric crohn's disease,” American Journal of Gastroenterology, vol. 104, no. 10, pp. 2566–2571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. R. Rosh, T. Lerer, J. Markowitz et al., “Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric crohns disease,” American Journal of Gastroenterology, vol. 104, no. 12, pp. 3042–3049, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. R. K. Russell, M. L. Wilson, S. Loganathan et al., “A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 8, pp. 946–953, 2011. View at Publisher · View at Google Scholar
  61. Y. Rosenbach, C. Hartman, R. Shapiro, A. Hirsch, Y. Avitzur, and R. Shamir, “Adalimumab treatment in children with refractory crohn's disease,” Digestive Diseases and Sciences, vol. 55, no. 3, pp. 747–753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. W. J. Sandborn, B. G. Feagan, S. Stoinov et al., “Certolizumab pegol for the treatment of Crohn's disease,” The New England Journal of Medicine, vol. 357, no. 3, pp. 228–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Schreiber, M. Khaliq-Kareemi, I. C. Lawrance et al., “Maintenance therapy with certolizumab pegol for Crohn's disease,” The New England Journal of Medicine, vol. 357, no. 3, pp. 239–250, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Schreiber, I. C. Lawrance, O. Ø. Thomsen, S. B. Hanauer, R. Bloomfield, and W. J. Sandborn, “Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease—subgroup results from a placebo-controlled study,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 2, pp. 185–193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. S. R. Targan, B. G. Feagan, R. N. Fedorak et al., “Natalizumab for the Treatment of Active Crohn's Disease: results of the ENCORE Trial,” Gastroenterology, vol. 132, no. 5, pp. 1672–1683, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. J. S. Hyams, D. C. Wilson, A. Thomas et al., “Natalizumab therapy for moderate to severe Crohn disease in adolescents,” Journal of Pediatric Gastroenterology and Nutrition, vol. 44, no. 2, pp. 185–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. K. J. Motil, R. J. Grand, L. Davis-Kraft, L. L. Ferlic, and E. O. Smith, “Growth failure in children with inflammatory bowel disease: a prospective study,” Gastroenterology, vol. 105, no. 3, pp. 681–691, 1993. View at Google Scholar · View at Scopus
  68. A. Sawczenko and B. K. Sandhu, “Presenting features of inflammatory bowel disease in Great Britain and Ireland,” Archives of Disease in Childhood, vol. 88, no. 11, pp. 995–1000, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Sawczenko, A. B. Ballinger, M. O. Savage, and I. R. Sanderson, “Clinical features affecting final adult height in patients with pediatric-onset crohn's disease,” Pediatrics, vol. 118, no. 1, pp. 124–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. E. A. Newby, A. Sawczenko, A. G. Thomas, and D. Wilson, “Interventions for growth failure in childhood Crohn's disease,” Cochrane Database of Systematic Reviews (Online), no. 3, article CD003873, 2005. View at Google Scholar · View at Scopus
  71. V. E. MacRae, S. C. Wong, C. Farquharson, and S. F. Ahmed, “Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review),” International Journal of Molecular Medicine, vol. 18, no. 6, pp. 1011–1018, 2006. View at Google Scholar · View at Scopus
  72. S. C. Wong, A. Smyth, E. McNeill et al., “The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation,” Clinical Endocrinology, vol. 73, no. 2, pp. 220–228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. L. M. Difedele, J. He, E. L. Bonkowski et al., “Tumor necrosis factor α blockade restores growth hormone signaling in murine colitis,” Gastroenterology, vol. 128, no. 5, pp. 1278–1291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. T. A. Ahmed, M. D. Buzzelli, C. H. Lang et al., “Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes,” American Journal of Physiology, vol. 292, no. 6, pp. G1793–G1803, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. V. E. MacRae, C. Farquharson, and S. F. Ahmed, “The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines,” Journal of Endocrinology, vol. 189, no. 2, pp. 319–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. A. M. Griffiths, A. R. Otley, J. Hyams et al., “A review of activity indices and end points for clinical trials in children with Crohn's disease,” Inflammatory Bowel Diseases, vol. 11, no. 2, pp. 185–196, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. T. D. Walters, A. R. Gilman, and A. M. Griffiths, “Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease,” Inflammatory Bowel Diseases, vol. 13, no. 4, pp. 424–430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Malik, S. Wong, J. Bishop et al., “Improvement in growth of children with crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction,” Journal of Pediatric Gastroenterology and Nutrition, vol. 52, no. 1, pp. 31–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. D. M. Sinitsky, D. A. Lemberg, S. T. Leach, T. D. Bohane, R. Jackson, and A. S. Day, “Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease,” Journal of Gastroenterology and Hepatology, vol. 25, no. 4, pp. 810–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Tuchman, M. Thayu, J. Shults, B. S. Zemel, J. M. Burnham, and M. B. Leonard, “Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease,” Journal of Pediatrics, vol. 153, no. 4, pp. 484–490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. S. E. Dubner, J. Shults, R. N. Baldassano et al., “Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease,” Gastroenterology, vol. 136, no. 1, pp. 123–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Thayu, M. B. Leonard, J. S. Hyams et al., “Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1378–1384, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Gilbert, X. He, P. Farmer et al., “Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumor necrosis factor-α,” The Journal of Biological Chemistry, vol. 277, no. 4, pp. 2695–2701, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. J. M. Radeff, Z. Nagy, and P. H. Stern, “Involvement of PKC-β in PTH, TNF-α, and IL-1β effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption,” Experimental Cell Research, vol. 268, no. 2, pp. 179–188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. W. V. Crandall and L. M. Mackner, “Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 1, pp. 75–84, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. T. C. Puchner, S. Kugathasan, K. J. Kelly, and D. G. Binion, “Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction,” Inflammatory Bowel Diseases, vol. 7, no. 1, pp. 34–37, 2001. View at Google Scholar
  87. C. Duburque, J. Lelong, R. Iacob et al., “Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 5, pp. 851–858, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Lahdenne, A. M. Wikström, K. Aalto, and K. L. Kolho, “Prevention of acute adverse events related to infliximab infusions in pediatric patients,” Arthritis Care & Research, vol. 62, no. 6, pp. 785–790, 2010. View at Google Scholar · View at Scopus
  89. G. C. Zella, M. E. Weinblatt, and H. S. Winter, “Drug-induced lupus associated with infliximab and adalimumab in an adolescent with crohn disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 49, no. 3, pp. 355–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. B. W. Behm and S. J. Bickston, “Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease,” Cochrane Database of Systematic Reviews, no. 1, p. CD006893, 2008. View at Google Scholar · View at Scopus
  91. M. Toruner, E. V. Loftus Jr., W. S. Harmsen et al., “Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease,” Gastroenterology, vol. 134, no. 4, pp. 929–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. W. S. Mow, M. T. Abreu-Martin, K. A. Papadakis, H. E. Pitchon, S. R. Targan, and E. A. Vasiliauskas, “High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy,” Clinical Gastroenterology and Hepatology, vol. 2, no. 4, pp. 309–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. M. J. Shale, C. H. Seow, C. S. Coffin, G. G. Kaplan, R. Panaccione, and S. Ghosh, “Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 1, pp. 20–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. W. Miehsler, G. Novacek, H. Wenzl et al., “A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 4, no. 3, pp. 221–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Arana, S. Allen, J. Burkowitz et al., “Infliximab paediatric crohns disease educational plan: a European, cross-sectional, multicentre evaluation,” Drug Safety, vol. 33, no. 6, pp. 489–501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Sellam, H. Hamdi, C. Roy et al., “Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy,” Annals of the Rheumatic Diseases, vol. 66, no. 12, pp. 1610–1615, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Salmon-Ceron, F. Tubach, O. Lortholary et al., “Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 616–623, 2011. View at Publisher · View at Google Scholar
  98. I. C. Lawrance, G. L. Radford-Smith, P. A. Bampton et al., “Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience,” Journal of Gastroenterology and Hepatology, vol. 25, no. 11, pp. 1732–1738, 2010. View at Publisher · View at Google Scholar
  99. I. Ferkolj, “How to improve the safety of biologic therapy in Crohn's disease,” Journal of Physiology and Pharmacology, vol. 60, supplement 7, pp. 67–70, 2009. View at Google Scholar
  100. K. Cheent, J. Nolan, S. Shariq, L. Kiho, A. Pal, and J. Arnold, “Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease,” Journal of Crohn's and Colitis, vol. 4, no. 5, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Hiremath, L. Duffy, and I. Leibowitz, “Infliximab-induced psoriasis in children with inflammatory bowel disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 52, no. 2, pp. 230–232, 2011. View at Publisher · View at Google Scholar
  102. J. M. Ko, A. B. Gottlieb, and J. F. Kerbleski, “Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases,” Journal of Dermatological Treatment, vol. 20, no. 2, pp. 100–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. M. G. Laukoetter, R. Mennigen, C. M. Hannig et al., “Intestinal cancer risk in Crohn's disease: a meta-analysis,” Journal of Gastrointestinal Surgery, vol. 15, no. 4, pp. 576–583, 2011. View at Publisher · View at Google Scholar
  104. P. Diak, J. Siegel, L. La Grenade, L. Choi, S. Lemery, and A. McMahon, “Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the food and drug administration,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2517–2524, 2010. View at Publisher · View at Google Scholar
  105. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W. J. Sandborn, and J. Colombel, “Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials,” Clinical Gastroenterology and Hepatology, vol. 6, no. 6, pp. 644–653, 2008. View at Publisher · View at Google Scholar
  106. C. A. Siegel, S. M. Marden, S. M. Persing, R. J. Larson, and B. E. Sands, “Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 8, pp. 874–881, 2009. View at Publisher · View at Google Scholar
  107. J. D. Lewis, W. B. Bilker, C. Brensinger, J. J. Deren, D. J. Vaughn, and B. L. Strom, “Inflammatory bowel disease is not associated with an increased risk of lymphoma,” Gastroenterology, vol. 121, no. 5, pp. 1080–1087, 2001. View at Google Scholar · View at Scopus
  108. D. S. Kotlyar, M. T. Osterman, R. H. Diamond et al., “A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease,” Clinical Gastroenterology and Hepatology, vol. 9, no. 1, pp. 36–41, 2011. View at Publisher · View at Google Scholar
  109. A. Kandiel, A. G. Fraser, B. I. Korelitz, C. Brensinger, and J. D. Lewis, “Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine,” Gut, vol. 54, no. 8, pp. 1121–1125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. M. K. White and K. Khalili, “Pathogenesis of progressive multifocal leukoencephalopathy—revisited,” Journal of Infectious Diseases, vol. 203, no. 5, pp. 578–586, 2011. View at Publisher · View at Google Scholar
  111. T. A. Yousry, E. O. Major, C. Ryschkewitsch et al., “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy,” The New England Journal of Medicine, vol. 354, no. 9, pp. 924–933, 2006. View at Publisher · View at Google Scholar · View at Scopus
  112. Biogen Idec., Tysabri Prescriber Information, Elan Pharmaceuticals, San Francisco, Calif, USA, 2010.
  113. P. H. Caldwell, S. B. Murphy, P. N. Butow, and J. C. Craig, “Clinical trials in children,” The Lancet, vol. 364, no. 9436, pp. 803–811, 2004. View at Publisher · View at Google Scholar · View at Scopus